Fangyan Zhong

Fangyan Zhong

Auto-generated profile, based on publicly available information

Fangyan Zhong

Department of Pathology The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2021 in Medicine
Verified
Journal Article
Open access
JLJunming Lai
Junming Lai
FZFangyan Zhong
Fangyan Zhong
JDJianxiong Deng
Jianxiong Deng
SHShuang Hu
Shuang Hu
RSRuoyan Shen
Ruoyan Shen
YLYongbiao Luo
Yongbiao Luo
Background: This meta-analysis evaluates the difference of sparing organs at risk (OAR) in different position (Prone position and Supine position) with different breathing patterns (Free breathing, FB/Deep inspiration breath hold, DIBH) for breast cancer patients receiving postoperative radiotherapy and provides a useful reference for clinical practice. Method: The relevant controlled trials of prone position versus supine position in postoperative radiotherapy for breast cancer were retrieved from the sources of PubMed, Cochrane Library, Embase, Web of Science and ClinicalTrails.gov. The principal outcome of interest was OAR doses (heart dose, left anterior descending coronary artery dose and ipsilateral lung dose) and target coverage. We mainly compared the effects of P-FB (Prone position FB) and S-FB (Supine position FB) and discussed the effects of DIBH combined with different positions on OAR dose in postoperative radiotherapy. We calculated summary standardized mean difference (SMD) and 95% confidence intervals (CI). The meta-analysis was performed using RevMan 5.4 software. Results: The analysis included 751 patients from 19 observational studies. Compared with the S-FB, the P-FB can have lower heart dose, left anterior descending coronary artery (LADCA) dose, and ipsilateral lung dose (ILL) more effectively, and the difference was statistically significant (heart dose, SMD = − 0.51, 95% CI − 0.66 ∼ − 0.36, P < .00001. LADCA dose, SMD = − 0.58, 95% CI – 0.85 ∼ − 0.31, P < .0001. ILL dose, SMD = − 2.84, 95% CI − 3.2 ∼ − 2.48, P < .00001). And there was no significant difference in target coverage between the S-FB and P-FB groups (SMD = − 0.1, 95% CI − 0.57 ∼ 0.36, P = .66). Moreover, through descriptive analysis, we found that P-DIBH (Prone position DIBH) has better sparing OAR than P-FB and S-DIBH (Supine position DIBH). Conclusion: By this meta-analysis, compared with the S-FB we found that implementation of P-FB in postoperative radiotherapy for breast cancer can reduce irradiation of heart dose, LADCA dose and ILL dose, without compromising mean dose of target coverage. Moreover, P-DIBH might become the most promising way for breast cancer patients to undergo radiotherapy.

3 February 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
JCJunjun Chen
Junjun Chen
TLTianzhu Lu
Tianzhu Lu
FZFangyan Zhong
Fangyan Zhong
QLQiaoli Lv
Qiaoli Lv
MFMin Fang
Min Fang
XGXiaochang Gong
Xiaochang Gong
This study aimed to construct a signature of N6-methyladenosine (m6A) regulator-related genes that could be used for the prognosis of head and neck squamous cell carcinoma (HNSCC) and to clarify the molecular and immune characteristics and benefits of immune checkpoint inhibitor (ICI) therapy using the prognostic signature to define the subgroups of HNSCC. This study showed that eighteen m6A regulators were abnormally expressed in the Cancer Genome Atlas (TCGA) HNSCC tissues compared with those in normal tissues. We constructed a signature of 12 m6A regulator-related genes using the Cox risk model, combined with the least absolute shrinkage and selection operator (Lasso) variable screening algorithm. Based on the median of the signature risk score, the patients were divided into high- and low-risk groups. The Kaplan–Meier survival analyses showed that patients with high-risk scores demonstrated poorer overall survival (OS) than those with low-risk scores based on TCGA-HNSCC data (p &lt;0.001). The OS of high-risk patients was significantly worse than that of low-risk patients in the GSE65858 (p &lt;0.001) and International Cancer Genome Consortium (ICGC) oral cancer cohorts (p = 0.0089). Furthermore, immune infiltration analyses showed that 8 types of immune cell infiltration showed highly significant differences between the two risk groups (p &lt;0.001). In the Imvigor210CoreBiologies dataset of patients who received ICIs, the objective response rate (ORR) of the low-risk group (32%) was significantly higher than that of the high-risk group (13%). Additionally, patients in the high-risk group presented with a more significant adverse OS than that of the low-risk group (p = 0.00032). GSE78220 also showed that the ORR of the low-risk group (64%) was higher than that of the high-risk group (43%) and the OS of low-risk patients was better than that of high-risk patients (p = 0.0064). The constructed prognostic signature, based on m6A regulator-related genes, could be used to effectively distinguish between prognoses for HNSCC patients. The prognostic signature was found to be related to the immune cell infiltration of HNSCC; it might help predict the responses and prognoses of ICIs during treatment.

11 December 2023 in Cancer Medicine
Verified
Journal Article
Open access
TLTian‐Zhu Lu
Tian‐Zhu Lu
FZFu‐Juan Zeng
Fu‐Juan Zeng
YHYu‐Jun Hu
Yu‐Jun Hu
MFMin Fang
Min Fang
FZFang‐Yan Zhong
Fang‐Yan Zhong
JLJingao Li
Jingao Li
Background and Purpose: To identify anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma (M1‐NPC).Materials and Methods: All M1‐NPC treated with chemotherapy and/or radiotherapy between 2010 and 2019 from two centers (training and validation cohort) were included. The prognostic value of metastatic disease extent and involved organs for overall survival (OS) were assessed by several multivariable analyses (MVA) models. A new M1 classification was proposed and validated in a separate cohort who received immuno‐chemotherapy.Results: A total of 197 M1‐NPC in the training and 307 in the validation cohorts were included for M1 subdivision study with median follow‐up of 46 and 57 months. MVA model with “≤2 organs/≤5 lesions” as the definition of oligometastasis had the highest C‐index (0.623) versus others (0.606–0.621). Patients with oligometastasis had better OS versus polymetastasis (hazard ratio [HR] 0.47/0.63) while liver metastases carried worse OS (HR 1.57/1.45) in MVA in the training/validation cohorts, respectively. We proposed to divide M1‐NPC into M1a (oligometastasis without liver metastases) and M1b (liver metastases or polymetastasis) with 3‐year OS of 66.5%/31.7% and 64.9%/35.0% in the training/validation cohorts, respectively. M1a subset had a better median progress‐free survival (not reach vs. 17 months, p < 0.001) in the immuno‐chemotherapy cohort (n = 163).Conclusion: Oligometastasis (≤2 organs/≤5 lesions) and liver metastasis are prognostic for M1‐NPC. Subdivision of M1‐NPC into M1a (oligometastasis without liver metastasis) and M1b (liver metastasis or polymetastasis) depicts the prognosis well in M1‐NPC patients who received immuno‐chemotherapy.

4 October 2026 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
YHYuJie Hu
YuJie Hu
QCQingfei Chu
Qingfei Chu
MLMengjia Lin
Mengjia Lin
YGYong Guo
Yong Guo
FZFangyan Zhong
Fangyan Zhong
CCChao Chen
Chao Chen